戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH(2)) and naltrindole.
2 kephalin on Na(V)1.7 levels was prevented by naltrindole.
3 y DPDPE were blocked by the delta antagonist naltrindole.
4 t genes were either up- or down-regulated by naltrindole.
5 t that rescued the deficit in PIT induced by naltrindole.
6 vely, but not the delta-selective antagonist naltrindole.
7 otency that is only partially antagonized by naltrindole.
8 a antagonist, albeit with lower potency than naltrindole.
9  the delta-1 and delta-2 receptor antagonist naltrindole.
10 R, bound to the subtype-selective antagonist naltrindole.
11  by a single injection of the DOR antagonist naltrindole.
12 d selective delta-opioid receptor antagonist naltrindole (1) and the spiroindanyl analogues 2 and 3,
13 gues of the delta opioid receptor antagonist naltrindole (1) possessing a phenyl, phenoxy, or benzylo
14 an the conformationally constrained ligands, naltrindole (1, NTI) and 7-(spiroindanyl)oxymorphone (2,
15 es (7 and 9) of the delta-selective ligands, naltrindole (1, NTI) and spiroindanyloxymorphone (2, SIO
16 mine, 0.1-20 microgram), or delta-selective (naltrindole, 1-20 microgram) opioid receptor antagonists
17                          DOR inhibition with naltrindole (10 microM) led to significant injury in nor
18                                              Naltrindole (10 microM), a delta-opioid receptor antagon
19                                              Naltrindole (10-100 microM) decreased amphetamine-evoked
20 ndole moiety in the delta-opioid antagonist, naltrindole (2, NTI), was employed as a scaffold to hold
21 hine, while pretreatment by the d-selective (naltrindole, 3 mg/kg) or the k-selective antagonist (nor
22 xone (5 mg/kg, sc), an opioid antagonist, or naltrindole (5 mg/kg, sc), a delta antagonist, blocked t
23 he delta opioid receptor-specific antagonist naltrindole (5 microg) did not.
24 e selective delta-opioid receptor antagonist naltrindole (500 nM).
25 AMGO: a mu-opioid selective agonist) and [3H]naltrindole (a delta-opioid selective antagonist) reveal
26                                              Naltrindole, a delta receptor antagonist, inhibited the
27         Pre-treatment prior to the swim with naltrindole, a selective delta-opioid receptor antagonis
28                                              Naltrindole, a selective DOR antagonist, abolished the i
29                                              Naltrindole, a selective DOR antagonist, abolished the i
30  the use of the selective radioligands [(3)H]naltrindole and [(3)H]norbinaltorphimine (nor-BNI) in co
31 d robust CoMFA models, a sizable data set of naltrindole and naltrexone analogues was assembled by po
32 osphorylated p38 immunoreactivity induced by naltrindole and reduced the neuronal injury.
33  can be labeled with the opiate alkaloid [3H]naltrindole and show greatly increased affinities toward
34 s (KDAN series) containing delta-antagonist (naltrindole) and kappa(1)-agonist (ICI-199,441) pharmaco
35 in (100, 500 microM), reversed the effect of naltrindole, confirming that delta receptors mediated th
36 e Akt/PKB signaling pathway, suggesting that naltrindole could be a potential lead for the developmen
37 orphine on all parameters measured, however, naltrindole (delta-selective antagonist, 2 micrograms/2
38 ,Pen7 amide or the delta-receptor antagonist naltrindole failed to block NSIA.
39                      Under these conditions, naltrindole had no effect on the calcium-independent com
40                                Lidocaine and naltrindole had no effect when injected into the dorsola
41 he side chain in 5'-substituted analogues of naltrindole has been further explored with the synthesis
42 rphine on GTP binding cannot be inhibited by naltrindole in the wild-type receptor.
43 and microscopic analyses clearly showed that naltrindole induced apoptosis in SCLC cells.
44  RNA interference experiments confirmed that naltrindole-induced cell death was associated with the A
45 m classical delta-opioid antagonists such as naltrindole into potent beta-arrestin-biased agonists.
46                                  Infusion of naltrindole into the accumbens shell abolished transfer
47 r-Pen-Thr-NH(2) (CTAP) or the DOR antagonist naltrindole into the core or shell subregions of the nuc
48                   Multiple microinfusions of naltrindole into the dorsal striatum or multiple systemi
49 infusion of SCH-23390 and the DOR antagonist naltrindole into the NAc-S also abolished PIT.
50            Together, these results show that naltrindole is a new inhibitor of the Akt/PKB signaling
51 ltrexamine (BFNA) or the delta 2 antagonist, naltrindole isothiocyanate (Ntii) in the periaqueductal
52 exone), mu (beta-funaltrexamine) and delta2 (naltrindole isothiocyanate) opioid antagonists administe
53 l (naltrexone), mu, kappa, delta1 or delta2 (naltrindole isothiocyanate) opioid antagonists into the
54 u(5), Cys(6)]-enkephalin (DALCE)), delta(2) (naltrindole isothiocyanate) or kappa(1) (nor-binaltorpha
55 6]-enkephalin: 10-40 micrograms) or delta 2 (naltrindole isothiocyanate: 20 micrograms) opioid subtyp
56  receptor affinity and antagonist potency of naltrindole (Ki = 0.29 nM, Ke = 0.49 nM).
57                                              Naltrindole (NTD) alone elicited a 75 +/- 30% increase i
58 c indium-labeled DOTA and DO3A conjugates of naltrindole (NTI) that are suited to in vivo studies of
59  delta opiate receptor-selective antagonists naltrindole (NTI), 7-benzylidenenaltrexone (BNTX) or nal
60        The delta-selective opioid antagonist naltrindole (NTI), as well as the kappa-selective opioid
61 ociceptive tolerance by the delta antagonist naltrindole (NTI), bivalent ligands [mu-delta agonist-an
62 ere found to be more mu/delta-selective than naltrindole (NTI).
63 A, mu), nor-binaltorphamine (NBNI, kappa) or naltrindole (NTI, delta).
64 t the delta-opioid receptor (DOR) antagonist naltrindole (NTI; 1 mum) did not, implicating MORs in fe
65  kappa (nor-binaltorphamine: NBNI) or delta (naltrindole: NTI) opioid antagonists in the VTA, and cor
66 is of the selective delta opioid antagonist, naltrindole, on extracellular striatal glutamate levels
67 e selective delta-opioid receptor antagonist naltrindole only partially blocked the effect of MMP-220
68 ckade of delta-opioid or VIP receptors using naltrindole or VIP6-28, respectively antagonized the VIP
69    Strikingly, chronic blockade of DOR using naltrindole partially improved motor coordination and no
70  Along with the injury, either by hypoxia or naltrindole, phosphorylated p38 increased in a major way
71 sion of the delta-opioid receptor antagonist naltrindole prevented tolerance development to morphine
72 iatum or multiple systemic administration of naltrindole reduces ethanol consumption, and following t
73                     Indolic N-benzylation of naltrindole reportedly extends the duration of delta-opi
74    Most strikingly, the same mutant exhibits naltrindole-sensitive etorphine-stimulated [35S]guanosin
75 her experiments revealed that the binding of naltrindole to delta opioid receptors could increase the
76                                 Furthermore, naltrindole treatment not only reduced the phosphorylati
77                                              Naltrindole treatment reduced constitutive phosphorylati
78 h the sensitivity of the three cell lines to naltrindole treatment.
79                  The delta-opioid antagonist naltrindole was inactive in both treatment groups.
80                             The Kd value for naltrindole was likewise unaffected by age.
81 rphinans, a range of 4-phenolic analogues of naltrindole were prepared and evaluated in in vitro assa
82 gonists (naltrexone, norbinaltorphimine, and naltrindole) were substantially less effective in produc
83  the delta-opioid receptor (DOPr) antagonist naltrindole when intraperitoneally injected in previous
84                          Here we report that naltrindole, which has been used as a classic delta opio